Left Ventricular Hypertrophy and Clinical Outcomes Over 5 Years After TAVR: An Analysis of the PARTNER Trials and Registries.

[1]  Deepak L. Bhatt,et al.  Left Ventricular Hypertrophy Does Not Affect 1-Year Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement. , 2019, JACC. Cardiovascular interventions.

[2]  P. Kellman,et al.  Reverse Myocardial Remodeling Following Valve Replacement in Patients With Aortic Stenosis , 2018, Journal of the American College of Cardiology.

[3]  J. Moon,et al.  Prevalence of Cardiac Amyloidosis in Patients Referred for Transcatheter Aortic Valve Replacement , 2018, Journal of the American College of Cardiology.

[4]  D. Forman,et al.  Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis , 2017, Journal of Cardiovascular Magnetic Resonance.

[5]  M. Dweck,et al.  Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis , 2017, JACC Cardiovascular Imaging.

[6]  M. Leon,et al.  Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement , 2017, European heart journal.

[7]  Theodore M. Hill,et al.  Is Load-Induced Ventricular Hypertrophy Ever Compensatory? , 2017, Circulation.

[8]  Tomohiko Taniguchi,et al.  Impact of the left ventricular mass index on the outcomes of severe aortic stenosis , 2017, Heart.

[9]  J. Leipsic,et al.  One-Year Clinical Outcomes With SAPIEN 3 Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Severe Aortic Stenosis , 2016, Circulation.

[10]  J. Leipsic,et al.  Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis , 2016, The Lancet.

[11]  M. Mack,et al.  Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. , 2016, The New England journal of medicine.

[12]  Joseph A. Hill,et al.  Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload. , 2015, Circulation.

[13]  B. Prendergast,et al.  A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial) , 2015, European heart journal cardiovascular Imaging.

[14]  Philippe Pibarot,et al.  Assessment of paravalvular regurgitation following TAVR: a proposal of unifying grading scheme. , 2015, JACC. Cardiovascular imaging.

[15]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[16]  Thoralf M Sundt,et al.  2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Journal of the American College of Cardiology.

[17]  Joseph A. Hill,et al.  Pathological Ventricular Remodeling: Mechanisms Part 1 of 2 , 2013, Circulation.

[18]  G. Bloomfield,et al.  Implementation of echocardiography core laboratory best practices: a case study of the PARTNER I trial. , 2013, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[19]  M. Dweck,et al.  Calcific aortic stenosis: a disease of the valve and the myocardium. , 2012, Journal of the American College of Cardiology.

[20]  M. Mack,et al.  Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. , 2012, Journal of the American College of Cardiology.

[21]  J. Pepper,et al.  Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. , 2011, Journal of the American College of Cardiology.

[22]  C. Lang,et al.  Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis. , 2011, Journal of the American College of Cardiology.

[23]  Stuart J Pocock,et al.  Transcatheter versus surgical aortic-valve replacement in high-risk patients. , 2011, The New England journal of medicine.

[24]  L. Thijs,et al.  Regression of Left Ventricular Mass by Antihypertensive Treatment: A Meta-Analysis of Randomized Comparative Studies , 2009, Hypertension.

[25]  J. Chambers,et al.  Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. , 2009, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[26]  Mario J. Garcia,et al.  Influence of concentric left ventricular remodeling on early mortality after aortic valve replacement. , 2008, The Annals of thoracic surgery.

[27]  J. Lommi,et al.  Left ventricular hypertrophy in aortic valve stenosis: preventive or promotive of systolic dysfunction and heart failure? , 2005, European heart journal.

[28]  Fernando Hornero Sos,et al.  Left ventricular mass index in aortic valve surgery: a new index for early valve replacement? , 2003, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[29]  K. Eagle,et al.  Implications of increased left ventricular mass index on in-hospital outcomes in patients undergoing aortic valve surgery. , 2001, The Journal of thoracic and cardiovascular surgery.

[30]  B. Lorell,et al.  Left ventricular hypertrophy: pathogenesis, detection, and prognosis. , 2000, Circulation.

[31]  R. Kerber,et al.  Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. , 2000, Circulation.

[32]  Clifford M. Hurvich,et al.  Smoothing parameter selection in nonparametric regression using an improved Akaike information criterion , 1998 .

[33]  Paul H. C. Eilers,et al.  Flexible smoothing with B-splines and penalties , 1996 .

[34]  J. Laragh,et al.  Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. , 1991, Annals of internal medicine.

[35]  D. Levy,et al.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.

[36]  J. Laragh,et al.  Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. , 1986, Annals of internal medicine.

[37]  N. Reichek,et al.  Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. , 1986, The American journal of cardiology.

[38]  W Grossman,et al.  Wall stress and patterns of hypertrophy in the human left ventricle. , 1975, The Journal of clinical investigation.